Catalent (NYSE:CTLT) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the stock.

A number of other research firms have also issued reports on CTLT. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Catalent has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Stock Performance

NYSE:CTLT opened at $63.48 on Friday. Catalent has a 52-week low of $41.15 and a 52-week high of $63.50. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The stock has a fifty day simple moving average of $61.74 and a 200-day simple moving average of $60.14. The company has a market capitalization of $11.52 billion, a PE ratio of -28.09, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.10) EPS. On average, equities research analysts expect that Catalent will post 0.78 earnings per share for the current fiscal year.

Insider Buying and Selling at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.31% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Catalent

Several institutional investors and hedge funds have recently bought and sold shares of CTLT. JPMorgan Chase & Co. increased its stake in Catalent by 15.1% during the third quarter. JPMorgan Chase & Co. now owns 1,520,308 shares of the company’s stock worth $92,085,000 after acquiring an additional 199,427 shares during the last quarter. Oddo BHF Asset Management Sas purchased a new stake in shares of Catalent during the 3rd quarter worth about $8,480,000. Tidal Investments LLC acquired a new stake in Catalent during the 3rd quarter worth approximately $214,000. Neo Ivy Capital Management purchased a new position in Catalent in the third quarter valued at approximately $1,078,000. Finally, Nomura Asset Management Co. Ltd. lifted its position in Catalent by 1.4% during the third quarter. Nomura Asset Management Co. Ltd. now owns 53,011 shares of the company’s stock valued at $3,211,000 after buying an additional 750 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.